hengrui glp 1 In a Phase 3 program reported by Kailera Therapeutics and partner Jiangsu Hengrui, two China trials of the oral small-molecule GLP-1 receptor agonist HRS-7535 met their primary goals in obesity and in Ribupatide, An Oral Dual GLP-1/GIP,
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30


























